Skip to content
2000
Volume 10, Issue 10
  • ISSN: 1389-4501
  • E-ISSN: 1873-5592

Abstract

Docetaxel is a chemotherapeutic drug which has recently demonstrated high efficacy in the treatment of a wide variety of tumors. Numerous novel targeted drugs are being introduced in preclinical and clinical practice, aiming to directly inhibit pathways responsible for the maintenance of transformed and immortalized phenotypes of cancer cells. Herein we reported the efficacy and safety results of the most significant clinical trials evaluating different combinations and schedules of docetaxel plus biological therapeutics.

Loading

Article metrics loading...

/content/journals/cdt/10.2174/138945009789578007
2009-10-01
2025-10-03
Loading full text...

Full text loading...

/content/journals/cdt/10.2174/138945009789578007
Loading

  • Article Type:
    Research Article
Keyword(s): BCL-2; Docetaxel; efficacy; EGFR; PDGFR; RTKI; safety; solid tumors; targeted therapy; VEGFR
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test